{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:27:35Z","timestamp":1778678855370,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Atropine is used to treat myopia, and choroidal thickness (ChT) has been suggested as a biomarker for treatment response. However, randomized controlled trials (RCTs) have reported inconsistent results regarding their efficacy. This study aimed to assess the effect of atropine on ChT in children with myopia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review and meta-analysis of RCTs was conducted using PubMed, Cochrane, Embase, and Web of Science databases, including trials registered online, from inception to March 2025. Eligible studies were those that involved patients aged &amp;lt;18\u202fyears with myopia treated using atropine sulfate eye drops and reported ChT outcomes. Meta-regression and the Cochrane <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> test were used to assess heterogeneity, respectively. Publication bias was evaluated using Funnel plots and Egger\u2019s and Begg\u2019s tests. Sensitivity analysis was used to examine the impact of individual studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 11 RCTs involving 1,784 eyes of children with myopia were included. Four doses of atropine (0.01, 0.025, 0.05, and 0.1%) were administered. Subfoveal ChT (SFChT) significantly thickened in the atropine group compared with the control group (placebo or spectacles) during the trial periods [weighted mean difference (WMD): 11.83\u202f\u03bcm, 95% confidence interval (CI): 0.88\u201322.79\u202f\u03bcm, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u202f=\u202f98.8%, <jats:italic>p<\/jats:italic>\u202f=\u202f0.000]. Additionally, 0.01% atropine showed the best effect in ChT changes at superior 1 and inferior 1 compared with control. Notably, 0.05% atropine demonstrated the most significantly thickened SFChT (WMD: 25.70\u202f\u03bcm, 95% CI: 17.46\u201333.94\u202f\u03bcm), had the best spherical equivalent control (WMD: 0.54 D, 95% CI: 0.38\u20130.70 D), and had the least axial length elongation (WMD: \u22120.21\u202fmm, 95% CI: \u22120.28 to 0.14\u202fmm).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results showed that atropine may increase ChT than control. Notably, 0.05% atropine may demonstrate the most favorable outcomes for ChT, spherical equivalent, and axial length.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/inplasy.com\/?s=INPLASY202320027<\/jats:uri>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1678698","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:34:25Z","timestamp":1759815265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of atropine on changes in choroidal thickness in children with myopia: a meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Li Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.preteyeres.2012.06.004","article-title":"The complex interactions of retinal, optical and environmental factors in myopia aetiology","volume":"31","author":"Flitcroft","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(21)00050-4","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/ICL.0000000000000207","article-title":"Myopia control: a review","volume":"42","author":"Walline","year":"2016","journal-title":"Eye Contact Lens"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bjophthalmol-2021-319306","article-title":"Interventions recommended for myopia prevention and control among children and adolescents in China: a systematic review","volume":"107","author":"Zhu","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0281816","DOI":"10.1371\/journal.pone.0281816","article-title":"A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine","volume":"18","author":"Nucci","year":"2023","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05, 0.025, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamaophthalmol.2023.5467","article-title":"Topical atropine for childhood myopia control: the atropine treatment long-term assessment study","volume":"142","author":"Li","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5, 0.1, and 0.01% doses (atropine for the treatment of myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/opo.12054","article-title":"Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning","volume":"33","author":"Nickla","year":"2013","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cxo.13128","article-title":"Comparisons of atropine versus cyclopentolate cycloplegia in myopic children","volume":"104","author":"Ye","year":"2021","journal-title":"Clin Exp Optom"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1167\/iovs.13-11732","article-title":"Choroidal thickness in childhood","volume":"54","author":"Read","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.61.14.15","article-title":"Effects of atropine treatment on choroidal thickness in myopic children","volume":"61","author":"Ye","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref17","first-page":"205","article-title":"Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism","volume":"34","author":"McBrien","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1509196","DOI":"10.3389\/fphar.2025.1509196","article-title":"The role of atropine in myopia control: insights into choroidal and scleral mechanisms","volume":"16","author":"Huang","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","article-title":"The association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study","volume":"237","author":"Yam","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5585441","DOI":"10.1155\/2021\/5585441","article-title":"A randomized controlled trial of the effect of 0.01% atropine eye drops combined with auricular acupoint stimulation on myopia progression","volume":"2021","author":"Kong","year":"2021","journal-title":"J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1440180","DOI":"10.3389\/fphar.2024.1440180","article-title":"Effects of atropine on choroidal thickness in myopic children: a meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.18240\/ijo.2023.03.17","article-title":"Choroidal thickness, myopia, and myopia control interventions in children: a meta-analysis and systemic review","volume":"16","author":"Meng","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","article-title":"IMI\u2014defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies","volume":"60","author":"Flitcroft","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"101348","DOI":"10.1016\/j.clae.2020.06.006","article-title":"Short-term effects of atropine combined with orthokeratology (ACO) on choroidal thickness","volume":"44","author":"Zhao","year":"2021","journal-title":"Cont Lens Anterior Eye"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1007\/s10792-021-01855-5","article-title":"Changes in subfoveal choroidal thickness in myopic children with 0.01% atropine, orthokeratology, or their combination","volume":"41","author":"Hao","year":"2021","journal-title":"Int Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40123-022-00476-0","article-title":"Short-term effects of atropine 0.01% on the structure and vasculature of the choroid and retina in myopic Chinese children","volume":"11","author":"Wang","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.65.10.21","article-title":"Choroidal changes during and after discontinuing long-term 0.01% atropine treatment for myopia control","volume":"65","author":"Lee","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-4977250\/v1","article-title":"Repeated monochromatic low-level red-light versus 0.01% atropine therapy for slowing myopia progression in children\u2014a randomized controlled trial","author":"Fu","year":""},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s40123-024-01051-5","article-title":"The macular choroidal thickness in Danish children with myopia after two-year low-dose atropine and one-year wash-out: a placebo-controlled randomized clinical trial","volume":"13","author":"Hansen","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17429","article-title":"Two-year changes of macular choroidal thickness in response to 0.01% atropine eye drops: results from the myopia outcome study of atropine in children (MOSAIC) clinical trial","author":"Kobia-Acquah","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"ref31","first-page":"887","article-title":"Effect of low-concentration atropine eyedrops on retinal and choroidal thickness and microcirculation in children and adolescents with myopia","volume":"43","author":"Zheng","year":"2023","journal-title":"Recent Adv Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/APO.0000000000000232","article-title":"Topical atropine in the control of myopia","volume":"5","author":"Tan","year":"2016","journal-title":"Asia Pac J Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/02713683.2020.1863431","article-title":"Change and recovery of choroid thickness after short-term application of 1% atropine gel and its influencing factors in 6\u20137-year-old children","volume":"46","author":"Jiang","year":"2021","journal-title":"Curr Eye Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"18310","DOI":"10.1038\/s41598-020-75342-9","article-title":"Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia","volume":"10","author":"Chiang","year":"2020","journal-title":"Sci Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000526448","article-title":"Changes of choroidal thickness in children after short-term application of 1% atropine gel","volume":"66","author":"Zhou","year":"2023","journal-title":"Ophthalmic Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"103528","DOI":"10.1016\/j.pdpdt.2023.103528","article-title":"Changes in choroidal thickness in myopic children with 0.01% atropine: evidence from a 12-month follow-up","volume":"42","author":"Wu","year":"2023","journal-title":"Photodiagn Photodyn Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.18240\/ijo.2024.06.19","article-title":"The optimal atropine concentration for myopia control in Chinese children: a systematic review and network Meta-analysis","volume":"17","author":"Wang","year":"2024","journal-title":"Int J Ophthalmol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41598-016-0002-7","article-title":"Nitric oxide (NO) mediates the inhibition of form-deprivation myopia by atropine in chicks","volume":"6","author":"Carr","year":"2016","journal-title":"Sci Rep"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.exer.2006.01.029","article-title":"Inhibiting the transient choroidal thickening response using the nitric oxide synthase inhibitor l-NAME prevents the ameliorative effects of visual experience on ocular growth in two different visual paradigms","volume":"83","author":"Nickla","year":"2006","journal-title":"Exp Eye Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/aos.14773","article-title":"The influence of the choroid on the onset and development of myopia: from perspectives of choroidal thickness and blood flow","volume":"99","author":"Liu","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1167\/iovs.18-25389","article-title":"Ocular biometric diurnal rhythms in emmetropic and myopic adults","volume":"59","author":"Burfield","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1678698\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:34:26Z","timestamp":1759815266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1678698\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":42,"alternative-id":["10.3389\/fmed.2025.1678698"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1678698","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1678698"}}